Hayyom Sharapov, CEO, Meros Pharm (Uzbekistan) shared insights on the Eurasia region strategy and the future of the pharmaceutical industry with the Global Pharmaceutical Leaders Club

In a world of rapidly evolving pharmaceutical markets, companies that can adapt to new challenges and maintain the highest standards of quality stand out. Meros Pharm, a leading pharmaceutical company in Uzbekistan, is one such company. Today, we have the pleasure of hearing from Hayyom Sharapov, CEO, Meros Pharm (Uzbekistan), as he shares his insights on the company’s priorities in the Eurasia region, its strategy for building long-term partnerships, and its ability to adapt to industry changes.

Here’s what he had to say about Meros Pharm’s strategy and prospects.

What are the priorities for your company in the Eurasia region? In which countries and what segments do you see the most prospects for your company?

For Meros Pharm, as the leading pharmaceutical company in Uzbekistan, building long-term relationships with partners is one of the priority strategic directions. We have been working with the leading manufacturers in Eastern Europe and the Caucasus for more than 10 years. For Meros Pharm the main value is to provide the population of Uzbekistan with high-quality, safe medicines, in order to ensure this we select only the most reliable manufacturers of pharmaceutical products.

What trends having the most impact on pharmaceutical markets in the countries of the Eurasian region do you highlight for your company?

Currently, the countries of the Eurasia region are experiencing developments in business culture. Business is becoming more transparent and structured, therefore, by building relationships with partners in Eurasian countries, Meros Pharm is improving its business processes, leveling up its employees’ professionalism and work in accordance with all the requirements and challenges of the contemporary pharmaceutical market.

What planned regulatory changes may affect the development of the pharmaceutical markets in the Eurasian region?

The global economy is currently going through a rather challenging turning point. Let us remember, for example, COVID which taught us to work remotely and other more serious political events taking place in Eurasia. These events do not slow down the development of the legal framework regulating the pharmaceutical market. As we see, all the introduced innovations are aimed at eliminating the import of counterfeit products and regulating prices, as a result, the consumer will receive high-quality pharmaceutical drugs at an affordable price.

Leave a Reply

Your email address will not be published. Required fields are marked *